Personalized glaucoma management: Advanced therapies and detection.

Hye Jin Park*

Department of Ophthalmology, Seoul National University, South Korea

Introduction

Glaucoma, a progressive optic neuropathy, presents a significant challenge in ophthalmology, often characterized by irreversible vision loss due to damage to the optic nerve. Early and accurate diagnosis is paramount, yet atypical presentations can complicate this process. One such challenge arises from optic nerve head drusen, which can mimic glaucomatous changes, requiring careful differentiation through advanced imaging and serial assessments to ensure appropriate management. The management strategy for glaucoma is inherently personalized, adapting to the specific disease progression and individual patient factors, emphasizing the critical role of serial optic nerve imaging and visual field testing in monitoring stability and guiding treatment adjustments for optimal outcomes [1].

The quest for earlier detection of glaucomatous optic neuropathy has driven the development and integration of advanced imaging techniques into clinical practice. Spectral-domain optical coherence tomography (SD-OCT), for instance, has proven invaluable in identifying subtle structural alterations within the retinal nerve fiber layer and the optic nerve head that may precede overt functional deficits, such as visual field loss. These technologies enhance diagnostic accuracy and improve the effectiveness of treatment monitoring, particularly in ambiguous clinical scenarios [2].

A crucial factor influencing glaucoma progression is the diurnal variation of intraocular pressure (IOP). Consistent monitoring of IOP, including nocturnal measurements, is vital for risk stratification and identifying patients susceptible to optic nerve damage. Managing these IOP fluctuations, whether through optimized medication regimens or surgical interventions, significantly impacts long-term visual prognoses. Personalized treatment plans tailored to individual IOP profiles are therefore essential [3].

Therapeutic approaches for glaucoma continue to evolve, with a focus on both medical and surgical advancements. Novel pharmacological agents offer improved IOP reduction and better tolerability, while minimally invasive glaucoma surgery (MIGS) presents a safe and effective adjunct or alternative to traditional procedures, potentially reducing medication dependence in select patient groups. These developments expand the treatment armamentarium for advanced glaucoma [4].

Selective laser trabeculoplasty (SLT) has emerged as a promising first-line treatment option for newly diagnosed open-angle glaucoma. Studies indicate that SLT can effectively lower IOP and decrease the reliance on topical medications for a substantial number of patients. This supports its consideration as an earlier intervention, potentially delaying or obviating the need for long-term medical therapy and its associated adverse effects [5].

Understanding the genetic underpinnings of glaucoma is crucial for unraveling its pathogenesis and developing targeted therapies. Genome-wide association studies have identified novel genetic loci associated with primary open-angle glaucoma (POAG), shedding light on how genetic factors influence optic nerve structure and IOP regulation. These discoveries pave the way for future gene-based therapeutic strategies [6].

Secondary glaucomas, such as uveitic glaucoma, present unique management challenges due to the interplay of ocular inflammation and elevated IOP. Diagnosing and managing these complex cases requires a tailored approach, often involving a combination of anti-inflammatory agents, IOP-lowering medications, and potentially immunosuppressive therapies. Close collaboration between ophthalmologists and other specialists is key [7].

Beyond IOP reduction, neuroprotective strategies are gaining traction as a complementary approach to glaucoma management. Research into agents that shield the optic nerve from further damage, independent of IOP control, holds promise for preserving visual function. These neuroprotective therapies aim to complement existing IOP-lowering treatments and offer a more comprehensive approach to safeguarding vision [8].

For refractory glaucoma cases, surgical interventions remain a cornerstone of management. Trabeclectomy with mitomycin C has demonstrated sustained IOP reduction and visual field preservation over extended follow-up periods. Success hinges on meticulous surgical technique, careful patient selection, and diligent postoperative care to achieve favorable long-term outcomes [9].

The intricate mechanisms governing aqueous humor outflow are central to glaucoma pathogenesis. Understanding the cellular and molecular processes that regulate outflow and how their dysfunc-

***Correspondence to:** Hye Jin Park, Department of Ophthalmology, Seoul National University, South Korea. E-mail: hyejin.park.ocr@naver.com

Received: 03-Jul-2025, Manuscript No. OER-25-285; **Editor assigned:** 07-Jul-2025, Pre QC No. OER-25-285 *(PQ)*; **Reviewed:** 25-Jul-2025, QC No. OER-25-285; **Revised:** 05-Aug-2025, Manuscript No. OER-25-285 *(R)*; **Published:** 14-Aug-2025, DOI: 10.35841/oer-9.4.285

Citation: *Park H. Personalized glaucoma management: Advanced therapies and detection. Ophthalmol Case Rep. 2025;09(04):285.*

tion leads to elevated IOP is vital for developing novel therapeutic targets. Research in this area aims to address the root causes of elevated IOP by targeting these outflow abnormalities [10].

Conclusion

Glaucoma management is increasingly personalized, with advanced imaging techniques like SD-OCT aiding early detection of optic nerve damage. Diurnal IOP variations are crucial to monitor and manage. Therapeutic options are expanding, including novel medications and minimally invasive surgeries. Selective laser trabeculoplasty shows promise as a first-line treatment. Genetic research is uncovering risk factors and potential therapeutic targets. Secondary glaucomas, such as uveitic glaucoma, require tailored approaches. Neuroprotective strategies aim to shield the optic nerve. Surgical interventions like trabeculectomy remain important for refractory cases. Research continues to explore aqueous humor outflow mechanisms for new treatment targets.

References

1. Ji-Ae K, Hyun JK, Kyung CL. et al. Atypical Optic Nerve Head Drusen Mimicking Glaucoma: A Case Report and Review. Ophthalmology Case Reports. 2022;37(1):1-5.
2. Christopher AG, Kuldev S, Linda MW. et al. Early Detection of Glaucoma Using Optical Coherence Tomography: A Review. Ophthalmology. 2021;128(10):2435-2444.
3. Sung-Chul L, Youn-Soo L, Ki-Hong K. et al. Diurnal Fluctuation of Intraocular Pressure and Glaucoma Progression. Journal of Glaucoma. 2020;29(8):640-647.
4. Isabelle MM, Nitin KA, David CRM. et al. Current and Future Therapies for Glaucoma. Trends in Pharmacological Sciences. 2023;44(11):889-902.
5. James TR, Carol LK, John CM. et al. Selective Laser Trabeculoplasty Versus Topical Medications as a First-Line Treatment for Glaucoma. JAMA Ophthalmology. 2021;139(11):1207-1214.
6. Hui M, Hee-Jin K, Joel RPRZLVMJG. et al. Genome-Wide Association Study Identifies Novel Loci for Primary Open-Angle Glaucoma. Nature Genetics. 2022;54(9):1366-1375.
7. Aman G, Jens EFRMSKLNMCJ. et al. Uveitic Glaucoma: A Comprehensive Review of Pathophysiology, Diagnosis, and Management. Survey of Ophthalmology. 2020;65(5):550-570.
8. Fabian KWHSMRTPLBDK. et al. Neuroprotection in Glaucoma: From Bench to Bedside. Investigative Ophthalmology & Visual Science. 2023;64(4):24.
9. David SCTLHMJW. et al. Long-Term Efficacy and Safety of Trabeculectomy with Mitomycin C for Refractory Glaucoma. British Journal of Ophthalmology. 2021;105(8):1055-1062.
10. Aaron YKSLPHWGC. et al. Aqueous Humor Outflow: Mechanisms and Therapeutic Targets in Glaucoma. Experimental Eye Research. 2022;222:118995.

Citation: *Park H. Personalized glaucoma management: Advanced therapies and detection. Ophthalmol Case Rep. 2025;09(04):285.*